Sponsor or institution

Clinical trials and research at Guangdong Association of Clinical Trials

• 11Clinical trials
• 1Country

Newest trials

All recruiting trials (11)

• Ivonescimab as first-line treatment for PD-L1 positive, driver gene-negative advanced NSCLC

  This real-world study tests whether Ivonescimab given as a first-line therapy helps patients with PD-L1 positive, driver gene-negative advanced NSCLC succeed with treatment and manage safety.

  Recruiting Guangdong Association of Clinical Trials · Guangzhou, Guangdong · NCT07696832

• RGL-270 with PD-1/PD-L1 Inhibitor for Advanced NSCLC

  This study tests whether adding RGL-270 to a PD-1/PD-L1 inhibitor is safe and may help people with advanced NSCLC.

  Recruiting Guangdong Association of Clinical Trials · Guangzhou, Other (Non U.s.) · NCT07652125

• PHOENIX: QL1706 plus chemo and bevacizumab in high PD-L1, driver-mutant non-squamous NSCLC

  This trial tests if adding QL1706 to chemotherapy and bevacizumab can help patients with PD-L1 high, driver-mutant non-squamous NSCLC after TKIs.

  Recruiting at 2 sites Phase 2 Guangdong Association of Clinical Trials · Guangzhou, Guangdong,China and 1 other locations · NCT07416058

• Chidamide plus Ivonescimab for advanced NSCLC with immune resistance and high YAP

  This phase II, single-arm study tests whether CHIDamide plus Ivonescimab can help adults with advanced NSCLC who have stopped responding to immunotherapy and have high YAP expression.

  Recruiting Phase 2 Guangdong Association of Clinical Trials · Guangzhou, Guangdong and 1 other locations · NCT07412262

• Osimertinib plus sacituzumab tirumotecan for EGFR-mutant advanced non-small cell lung cancer with persistent ctDNA after initial osimertinib

  This trial will test whether adding sacituzumab tirumotecan to osimertinib helps people with advanced EGFR-mutant non-small cell lung cancer whose blood ctDNA remains positive after one cycle of osimertinib.

  Recruiting at 4 sites Phase 2 Guangdong Association of Clinical Trials · Guangzhou, Guangdong and 3 other locations · NCT07375316

• IBI351 with cetuximab β for previously untreated advanced KRAS G12C non-small cell lung cancer

  This trial tests whether combining IBI351 with cetuximab β helps people with untreated advanced non-small cell lung cancer that has a KRAS G12C mutation.

  Recruiting at 5 sites Phase 2 Guangdong Association of Clinical Trials · Guangzhou, Guangdong and 6 other locations · NCT07198841

• Adaptive adjuvant sintilimab treatment guided by MRD for resected Stage II–IIIB NSCLC

  This trial tests whether using postoperative blood MRD tests to guide adjuvant sintilimab helps people with resected Stage II–IIIB NSCLC who did not achieve a complete response after neoadjuvant chemo‑immunotherapy.

  Recruiting at 2 sites Phase 2 Guangdong Association of Clinical Trials · Guangzhou, Guangdong and 1 other locations · NCT07120698

• First-line treatment with lorlatinib for advanced ALK+ lung cancer in China

  This study is testing if lorlatinib can be an effective first treatment for people in China with advanced ALK-positive lung cancer.

  Recruiting Phase 2 Guangdong Association of Clinical Trials · Guangzhou, Guangdong · NCT06092086

• Adjuvant treatment for EGFR mutant non-small cell lung cancer based on MRD status

  This study is testing if a specific cancer treatment can help people with a certain type of lung cancer after surgery, based on whether they have leftover cancer cells in their body.

  Recruiting Phase 2 Guangdong Association of Clinical Trials · Beijing and 15 other locations · NCT05536505

• Omitting adjuvant therapy for lung cancer patients with undetectable molecular residual disease

  This study is testing whether lung cancer patients who have no detectable cancer signs after surgery can safely skip additional treatment and just be monitored.

  Recruiting at 5 sites Guangdong Association of Clinical Trials · Foshan, Guangdong and 4 other locations · NCT05457049

• Evaluating neoadjuvant immunotherapy for early stage lung cancer in China

  This study is testing if a new type of immunotherapy, alone or with chemotherapy, can help people with early-stage lung cancer in China feel better and live longer.

  Recruiting Guangdong Association of Clinical Trials · Guangzhou, Guangdong · NCT04286841

Quick answers

How many clinical trials run by Guangdong Association of Clinical Trials are recruiting right now?

11, as of November 12, 2026. We update this list each time we refresh our data from ClinicalTrials.gov.

Where are these trials running?

All of them have sites in China. Each study page lists its sites and which ones are recruiting.

What phases are they in?

Phase 2: 7. Trials with no phase listed are usually device, behavioural or observational studies.

How do I join one?

Open a study, check the "Is this trial a fit for you?" section, then contact the study team listed on the page. They will ask a few screening questions. Asking is free and does not commit you to anything. Talk it over with your doctor first.

Find the studies that fit you

A list is a starting point. Tell us your situation in your own words and we'll rank the studies that match and explain why. It's free and needs no account.

Describe your situation →